Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
A Travere informou que seu medicamento renal FILSPARI continua ganhando tração tanto na nefropatia por IgA (IgAN) quanto na ...
Travere Therapeutics teilte am Mittwoch mit, dass das Unternehmen vom US-Patent- und Markenamt eine Mitteilung über die ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Investing.com - Guggenheim ha alzato il proprio obiettivo di prezzo su Travere Therapeutics ( NASDAQ:TVTX) a $89 da $75 ...
Travere Therapeutics, Inc. und Eric Dube, Ph.D., haben am 21. September 2026 im gegenseitigen Einvernehmen den Zeitplan und ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Tidligere festivalsjef Mats Aronsen og musiker Bård Torstensen ønsker å redde festivalen Canal Street i Arendal, som er truet av konkurs. Festivalen har vært arrangert siden 1996, men anstrengt økonom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results